Published in Diabetologia on March 04, 2005
Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications. Hepatology (2010) 5.35
Liver, muscle, and adipose tissue insulin action is directly related to intrahepatic triglyceride content in obese subjects. Gastroenterology (2008) 3.04
Alterations in adipose tissue and hepatic lipid kinetics in obese men and women with nonalcoholic fatty liver disease. Gastroenterology (2007) 2.29
Plasma metabolomic profile in nonalcoholic fatty liver disease. Metabolism (2010) 1.77
Non-alcoholic fatty liver disease (NAFLD) and its connection with insulin resistance, dyslipidemia, atherosclerosis and coronary heart disease. Nutrients (2013) 1.73
Redox mechanisms in hepatic chronic wound healing and fibrogenesis. Fibrogenesis Tissue Repair (2008) 1.30
Dissociation between intrahepatic triglyceride content and insulin resistance in familial hypobetalipoproteinemia. Gastroenterology (2010) 1.27
Alterations in fatty acid kinetics in obese adolescents with increased intrahepatic triglyceride content. Obesity (Silver Spring) (2008) 1.27
High fat diet induced hepatic steatosis establishes a permissive microenvironment for colorectal metastases and promotes primary dysplasia in a murine model. Am J Pathol (2009) 1.25
Adipose-specific disruption of signal transducer and activator of transcription 3 increases body weight and adiposity. Endocrinology (2007) 1.25
Effect of fenofibrate and niacin on intrahepatic triglyceride content, very low-density lipoprotein kinetics, and insulin action in obese subjects with nonalcoholic fatty liver disease. J Clin Endocrinol Metab (2010) 1.21
PNPLA3 I148M polymorphism and progressive liver disease. World J Gastroenterol (2013) 1.18
Chronic enrichment of hepatic endoplasmic reticulum-mitochondria contact leads to mitochondrial dysfunction in obesity. Nat Med (2014) 1.18
Genetic predisposition in NAFLD and NASH: impact on severity of liver disease and response to treatment. Curr Pharm Des (2013) 1.16
Pentoxifylline decreases oxidized lipid products in nonalcoholic steatohepatitis: new evidence on the potential therapeutic mechanism. Hepatology (2012) 1.14
Increased whole-body adiposity without a concomitant increase in liver fat is not associated with augmented metabolic dysfunction. Obesity (Silver Spring) (2010) 1.14
Ectopic fat and insulin resistance: pathophysiology and effect of diet and lifestyle interventions. Int J Endocrinol (2012) 1.14
Non-alcoholic fatty liver disease: The diagnosis and management. World J Hepatol (2015) 1.11
Viewpoints on the way to a consensus session: where does insulin resistance start? The liver. Diabetes Care (2009) 1.10
A maternal high-fat diet is accompanied by alterations in the fetal primate metabolome. Am J Obstet Gynecol (2009) 1.09
Integrated control of hepatic lipogenesis versus glucose production requires FoxO transcription factors. Nat Commun (2014) 1.08
Insulin resistance predicts mortality in nondiabetic individuals in the U.S. Diabetes Care (2010) 1.04
Fatty liver index predicts further metabolic deteriorations in women with previous gestational diabetes. PLoS One (2012) 1.00
The I148M PNPLA3 polymorphism influences serum adiponectin in patients with fatty liver and healthy controls. BMC Gastroenterol (2012) 1.00
Metabolic consequences of ENPP1 overexpression in adipose tissue. Am J Physiol Endocrinol Metab (2011) 1.00
Intra-thoracic fat, cardiometabolic risk factors, and subclinical cardiovascular disease in healthy, recently menopausal women screened for the Kronos Early Estrogen Prevention Study (KEEPS). Atherosclerosis (2011) 0.99
Lipids in the wrong place: visceral fat and nonalcoholic steatohepatitis. Diabetes Care (2011) 0.99
Obesity as the common soil of non-alcoholic fatty liver disease and diabetes: Role of adipokines. J Diabetes Investig (2013) 0.99
E4orf1 improves lipid and glucose metabolism in hepatocytes: a template to improve steatosis & hyperglycemia. PLoS One (2012) 0.99
Bisphenol A and Metabolic Syndrome: Results from NHANES. Int J Endocrinol (2012) 0.96
Treatment of Nonalcoholic Fatty Liver Disease: The Role of Medical, Surgical, and Endoscopic Weight Loss. J Clin Transl Hepatol (2015) 0.95
Viewpoints on the way to the consensus session: where does insulin resistance start? The adipose tissue. Diabetes Care (2009) 0.94
Pathogenesis and therapeutic approaches for non-alcoholic fatty liver disease. World J Hepatol (2014) 0.94
Nonalcoholic Fatty liver: a possible new target for type 2 diabetes prevention and treatment. Int J Mol Sci (2013) 0.94
Lipoprotein subfractions in metabolic syndrome and obesity: clinical significance and therapeutic approaches. Nutrients (2013) 0.94
Ectopic fat accumulation and distant organ-specific insulin resistance in Japanese people with nonalcoholic fatty liver disease. PLoS One (2014) 0.93
Genetic Factors in the Pathogenesis of Nonalcoholic Fatty Liver and Steatohepatitis. Biomed Res Int (2015) 0.93
Relation between augmentation index and adiponectin during one-year metformin treatment for nonalcoholic steatohepatosis: effects beyond glucose lowering? Cardiovasc Diabetol (2012) 0.93
Hepatic Steatosis as a Marker of Metabolic Dysfunction. Nutrients (2015) 0.92
Role of innate immune response in non-alcoholic Fatty liver disease: metabolic complications and therapeutic tools. Front Immunol (2014) 0.92
Prevalence of non-alcoholic fatty liver disease in children and relationship to metabolic syndrome, insulin resistance, and waist circumference. Environ Health Prev Med (2009) 0.92
The in utero programming effect of increased maternal androgens and a direct fetal intervention on liver and metabolic function in adult sheep. PLoS One (2011) 0.91
Dyslipidaemia of obesity, metabolic syndrome and type 2 diabetes mellitus: the case for residual risk reduction after statin treatment. Open Cardiovasc Med J (2011) 0.90
Reduced intrahepatic fat content is associated with increased whole-body lipid oxidation in patients with type 1 diabetes. Diabetologia (2005) 0.90
Hepatic notch signaling correlates with insulin resistance and nonalcoholic fatty liver disease. Diabetes (2013) 0.89
Dietary anthocyanins as nutritional therapy for nonalcoholic fatty liver disease. Oxid Med Cell Longev (2013) 0.89
Moro orange juice prevents fatty liver in mice. World J Gastroenterol (2012) 0.88
The A736V TMPRSS6 polymorphism influences hepatic iron overload in nonalcoholic fatty liver disease. PLoS One (2012) 0.88
The Subtle Balance between Lipolysis and Lipogenesis: A Critical Point in Metabolic Homeostasis. Nutrients (2015) 0.87
Elevated hepatic fatty acid oxidation, high plasma fibroblast growth factor 21, and fasting bile acids in nonalcoholic steatohepatitis. Eur J Gastroenterol Hepatol (2011) 0.87
Coordinated defects in hepatic long chain fatty acid metabolism and triglyceride accumulation contribute to insulin resistance in non-human primates. PLoS One (2011) 0.87
Nutrition and nonalcoholic Fatty liver disease: the significance of cholesterol. Int J Hepatol (2012) 0.86
Non-alcoholic fatty liver disease may develop in individuals with normal body mass index. Ann Gastroenterol (2012) 0.86
Clinicopathological characteristics and metabolic profiles of non-alcoholic fatty liver disease in Indian patients with normal body mass index: Do they differ from obese or overweight non-alcoholic fatty liver disease? Indian J Endocrinol Metab (2013) 0.86
Association between Serum Albumin, Insulin Resistance, and Incident Diabetes in Nondiabetic Subjects. Endocrinol Metab (Seoul) (2013) 0.86
Nonalcoholic fatty liver disease and polycystic ovary syndrome. World J Gastroenterol (2014) 0.84
Peroxisome proliferator-activated receptor genetic polymorphisms and nonalcoholic Fatty liver disease: any role in disease susceptibility? PPAR Res (2013) 0.84
Abdominal subcutaneous adipose tissue insulin resistance and lipolysis in patients with non-alcoholic steatohepatitis. Diabetes Obes Metab (2014) 0.84
Dissociation of hepatic insulin resistance from susceptibility of nonalcoholic fatty liver disease induced by a high-fat and high-carbohydrate diet in mice. Am J Physiol Gastrointest Liver Physiol (2014) 0.84
Glucose-induced glucagon-like Peptide 1 secretion is deficient in patients with non-alcoholic fatty liver disease. PLoS One (2014) 0.84
Metabolic inflexibility and insulin resistance in obese adolescents with non-alcoholic fatty liver disease. Pediatr Diabetes (2014) 0.84
Effects of acute glucocorticoid blockade on metabolic dysfunction in patients with Type 2 diabetes with and without fatty liver. Am J Physiol Gastrointest Liver Physiol (2014) 0.83
Nonalcoholic fatty liver disease markers are associated with insulin resistance in type 1 diabetes. Dig Dis Sci (2011) 0.83
Steatosis and steatohepatitis: complex disorders. Int J Mol Sci (2014) 0.83
Non-alcoholic fatty liver disease and diabetes: from physiopathological interplay to diagnosis and treatment. World J Gastroenterol (2014) 0.83
Hepatic fatty acid trafficking: multiple forks in the road. Adv Nutr (2013) 0.82
The Relationship between Type 2 Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease Measured by Controlled Attenuation Parameter. Yonsei Med J (2016) 0.82
Microbiota and nonalcoholic steatohepatitis. Semin Immunopathol (2013) 0.82
Pathophysiology of Non Alcoholic Fatty Liver Disease. Int J Mol Sci (2016) 0.81
White Pitaya (Hylocereus undatus) Juice Attenuates Insulin Resistance and Hepatic Steatosis in Diet-Induced Obese Mice. PLoS One (2016) 0.81
Incretin based therapies: a novel treatment approach for non-alcoholic fatty liver disease. World J Gastroenterol (2014) 0.81
MicroRNA-185 regulates expression of lipid metabolism genes and improves insulin sensitivity in mice with non-alcoholic fatty liver disease. World J Gastroenterol (2014) 0.81
Fatty liver disease in diabetes mellitus. Hepatobiliary Surg Nutr (2015) 0.81
HCC development is associated to peripheral insulin resistance in a mouse model of NASH. PLoS One (2014) 0.81
Insulin resistance in development and progression of nonalcoholic fatty liver disease. World J Gastrointest Pathophysiol (2016) 0.81
Nonalcoholic fatty liver disease and hepatic cirrhosis: Comparison with viral hepatitis-associated steatosis. World J Gastroenterol (2015) 0.80
Ghrelin-ghrelin O-acyltransferase system in the pathogenesis of nonalcoholic fatty liver disease. World J Gastroenterol (2015) 0.79
Ectopic fat and adipokines in metabolically benign overweight/obese women: the Kronos Early Estrogen Prevention Study. Obesity (Silver Spring) (2013) 0.79
Simple modeling allows prediction of steady-state glucose disposal rate from early data in hyperinsulinemic glucose clamps. Am J Physiol Endocrinol Metab (2009) 0.79
Nonalcoholic Fatty Liver Disease: Clinical Features and Pathogenesis. Gastroenterol Hepatol (N Y) (2006) 0.78
Obesity-Related Digestive Diseases and Their Pathophysiology. Gut Liver (2016) 0.78
Nonalcoholic fatty liver disease as a multi-systemic disease. World J Gastroenterol (2016) 0.78
Probiotics as a complementary therapeutic approach in nonalcoholic fatty liver disease. World J Hepatol (2015) 0.78
Nonalcoholic steatohepatitis and insulin resistance in children. World J Diabetes (2014) 0.78
Nonalcoholic Fatty liver disease/non-alcoholic steatohepatitis in childhood: endocrine-metabolic "mal-programming". Hepat Mon (2014) 0.78
Are women with polycystic ovarian syndrome at a high risk of non-alcoholic Fatty liver disease; a meta-analysis. Hepat Mon (2014) 0.78
Micronutrient Antioxidants and Nonalcoholic Fatty Liver Disease. Int J Mol Sci (2016) 0.77
Characteristics of nonalcoholic fatty liver disease induced in wistar rats following four different diets. Nutr Res Pract (2015) 0.77
Type 2 Diabetes in Non-Alcoholic Fatty Liver Disease and Hepatitis C Virus Infection-Liver: The "Musketeer" in the Spotlight. Int J Mol Sci (2016) 0.76
Risk factors of chronic hepatitis in antiretroviral-treated HIV infection, without hepatitis B or C viral infection. AIDS Res Ther (2013) 0.76
Pathogenesis and Prevention of Hepatic Steatosis. Gastroenterol Hepatol (N Y) (2015) 0.76
Effect of Global ATGL Knockout on Murine Fasting Glucose Kinetics. J Diabetes Res (2015) 0.75
Heme oxygenase-1 gene promoter polymorphism and the risk of pediatric nonalcoholic fatty liver disease. Int J Obes (Lond) (2015) 0.75
Atherosclerosis and Liver Function Tests in Coronary Angiography Patients. West Indian Med J (2015) 0.75
Association between metabolic syndrome and liver histology among NAFLD patients without diabetes. BMJ Open Gastroenterol (2016) 0.75
Beneficial Effect of Synbiotic Supplementation on Hepatic Steatosis and Anthropometric Parameters, But Not on Gut Permeability in a Population with Nonalcoholic Steatohepatitis. Nutrients (2016) 0.75
Gender Specific Association of Serum Leptin and Insulinemic Indices with Nonalcoholic Fatty Liver Disease in Prediabetic Subjects. PLoS One (2015) 0.75
Strong and persistent effect on liver fat with a Paleolithic diet during a two-year intervention. Int J Obes (Lond) (2016) 0.75
A Computational Model of Hepatic Energy Metabolism: Understanding Zonated Damage and Steatosis in NAFLD. PLoS Comput Biol (2016) 0.75
Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia (2012) 10.74
Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care (1991) 9.95
Pathogenesis of NIDDM. A balanced overview. Diabetes Care (1992) 6.56
delta Agent: association of delta antigen with hepatitis B surface antigen and RNA in serum of delta-infected chimpanzees. Proc Natl Acad Sci U S A (1980) 5.12
Transmission of the hepatitis B virus-associated delta antigen to chimpanzees. J Infect Dis (1980) 4.28
Effect of fatty acids on glucose production and utilization in man. J Clin Invest (1983) 4.00
The metabolic syndrome: time for a critical appraisal. Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia (2005) 3.97
Insulin resistance in essential hypertension. N Engl J Med (1987) 3.78
The delta agent. Hepatology (1983) 3.72
Hepatitis delta virus: protein composition of delta antigen and its hepatitis B virus-derived envelope. J Virol (1986) 3.63
Regulation of endogenous fat and carbohydrate metabolism in relation to exercise intensity and duration. Am J Physiol (1993) 3.53
Glucose and free fatty acid metabolism in non-insulin-dependent diabetes mellitus. Evidence for multiple sites of insulin resistance. J Clin Invest (1989) 3.03
Types of 'reticulin' antibodies detected in human sera by immunofluorescence. J Clin Pathol (1973) 2.98
Delta hepatitis agent: structural and antigenic properties of the delta-associated particle. Infect Immun (1984) 2.81
Beta-cell dysfunction and glucose intolerance: results from the San Antonio metabolism (SAM) study. Diabetologia (2003) 2.80
Acute effects of gastric bypass versus gastric restrictive surgery on beta-cell function and insulinotropic hormones in severely obese patients with type 2 diabetes. Int J Obes (Lond) (2009) 2.70
Why are clinical laboratory tests performed? When are they valid? JAMA (1975) 2.66
Microsomal antibodies in active chronic hepatitis and other disorders. Clin Exp Immunol (1973) 2.59
The hepatitis B virus-associated delta antigen: isolation from liver, development of solid-phase radioimmunoassays for delta antigen and anti-delta and partial characterization of delta antigen. J Immunol (1980) 2.57
Hepatic and peripheral insulin resistance: a common feature of type 2 (non-insulin-dependent) and type 1 (insulin-dependent) diabetes mellitus. Diabetologia (1982) 2.48
Regulation of splanchnic and peripheral glucose uptake by insulin and hyperglycemia in man. Diabetes (1983) 2.45
Influence of delta infection on severity of hepatitis B. Lancet (1982) 2.31
Incidence and significance of antibodies to delta antigen in hepatitis B virus infection. Lancet (1979) 2.29
Fasting hyperglycemia in non-insulin-dependent diabetes mellitus: contributions of excessive hepatic glucose production and impaired tissue glucose uptake. Metabolism (1989) 2.27
Effect of insulin on uric acid excretion in humans. Am J Physiol (1995) 2.25
Epidemiology of HBV-associated delta agent: geographical distribution of anti-delta and prevalence in polytransfused HBsAg carriers. Lancet (1980) 2.17
Chronic hepatitis in carriers of hepatitis B surface antigen, with intrahepatic expression of the delta antigen. An active and progressive disease unresponsive to immunosuppressive treatment. Ann Intern Med (1983) 2.16
Noradrenalin vs terlipressin in patients with hepatorenal syndrome: a prospective, randomized, unblinded, pilot study. J Hepatol (2007) 2.12
Influence of hyperinsulinemia, hyperglycemia, and the route of glucose administration on splanchnic glucose exchange. Proc Natl Acad Sci U S A (1978) 2.08
Decreased globin messenger RNA in thalassemia detected by molecular hybridization. Proc Natl Acad Sci U S A (1973) 2.07
Clinical and biochemical features of muscle dysfunction in subclinical hypothyroidism. J Clin Endocrinol Metab (1997) 2.04
Estimated glomerular filtration rate, albuminuria and mortality in type 2 diabetes: the Casale Monferrato study. Diabetologia (2007) 2.01
The state of hepatitis B and C in Europe: report from the hepatitis B and C summit conference*. J Viral Hepat (2011) 2.00
Efficacy of amoxycillin plus clavulanic acid-based triple therapy for Helicobacter pylori eradication: a retrospective study. Panminerva Med (2010) 1.99
Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials. Diabetologia (2012) 1.98
Abnormal or absent beta mRNA in betao Ferrara and gene deletion in delta beta thalassaemia. Nature (1976) 1.96
The disposal of an oral glucose load in healthy subjects. A quantitative study. Diabetes (1985) 1.88
Early-onset type 2 diabetes in obese white subjects is characterised by a marked defect in beta cell insulin secretion, severe insulin resistance and a lack of response to aerobic exercise training. Diabetologia (2007) 1.82
Splanchnic and peripheral disposal of oral glucose in man. Diabetes (1983) 1.82
Roux-en-Y gastric bypass and sleeve gastrectomy: mechanisms of diabetes remission and role of gut hormones. J Clin Endocrinol Metab (2013) 1.82
Role of lipid oxidation in pathogenesis of insulin resistance of obesity and type II diabetes. Diabetes (1987) 1.76
Acute elevation of free fatty acid levels leads to hepatic insulin resistance in obese subjects. Metabolism (1987) 1.76
Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study. Diabetes Obes Metab (2010) 1.76
Chronic hepatitis in HBsAg carriers with serum HBV-DNA and anti-HBe. Gastroenterology (1986) 1.75
Obesity and insulin resistance in humans: a dose-response study. Metabolism (1990) 1.74
Coronary hemodynamics and myocardial metabolism in patients with syndrome X: response to pacing stress. J Am Coll Cardiol (1991) 1.68
Impaired beta cell glucose sensitivity rather than inadequate compensation for insulin resistance is the dominant defect in glucose intolerance. Diabetologia (2010) 1.64
Hepatic disorders associated with liver-kidney microsomal antibodies. Br Med J (1974) 1.64
Impaired beta cell glucose sensitivity and whole-body insulin sensitivity as predictors of hyperglycaemia in non-diabetic subjects. Diabetologia (2005) 1.61
The metabolic profile of NIDDM is fully established in glucose-tolerant offspring of two Mexican-American NIDDM parents. Diabetes (1992) 1.60
Effect of levothyroxine replacement on lipid profile and intima-media thickness in subclinical hypothyroidism: a double-blind, placebo- controlled study. J Clin Endocrinol Metab (2004) 1.59
Synergistic interaction between exercise and insulin on peripheral glucose uptake. J Clin Invest (1981) 1.59
New concepts in the pathogenesis and treatment of noninsulin-dependent diabetes mellitus. Am J Med (1983) 1.59
Influence of obesity and type 2 diabetes on gluconeogenesis and glucose output in humans: a quantitative study. Diabetes (2000) 1.57
The role of free fatty acid metabolism in the pathogenesis of insulin resistance in obesity and noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab (1991) 1.57
Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone. Diabetes Care (2001) 1.56
Coronary atherosclerosis in Type II diabetes: angiographic findings and clinical outcome. Diabetologia (2000) 1.54
Chronic Helicobacter pylori infection and migraine: a case-control study. Headache (2001) 1.54
The role of beta-cell function and insulin sensitivity in the remission of type 2 diabetes after gastric bypass surgery. J Clin Endocrinol Metab (2011) 1.53
Sequential versus concomitant administration of ribavirin and interferon alfa-n3 in patients with chronic hepatitis C not responding to interferon alone: results of a randomized, controlled trial. Hepatology (1998) 1.53
Insulin sensitivity, vascular reactivity, and clamp-induced vasodilatation in essential hypertension. Circulation (1997) 1.53
Long-term results with interferon therapy in chronic type B hepatitis: a prospective randomized trial. Am J Gastroenterol (1999) 1.52
Systemic inhibition of nitric oxide synthesis in non-diabetic individuals produces a significant deterioration in glucose tolerance by increasing insulin clearance and inhibiting insulin secretion. Diabetologia (2013) 1.51
Management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy. Update regarding the thiazolidinediones. Diabetologia (2008) 1.50
Characterization of the microsomal antigen related to a subclass of active chronic hepatitis. Immunology (1974) 1.50
Serological response to the hepatitis delta virus in hepatitis D. Lancet (1987) 1.50
Helicobacter pylori seroprevalence in cirrhotic patients with hepatitis B virus infection. Neth J Med (2000) 1.50
Multicentre study of prevalence of HBV-associated delta infection and liver disease in drug-addicts. Lancet (1982) 1.50
Effect of insulin on the distribution and disposition of glucose in man. J Clin Invest (1985) 1.49
Systemic nitric oxide production and renal function in nonazotemic human cirrhosis: a reappraisal. Am J Gastroenterol (2002) 1.49
Infection with the delta agent in chronic HBsAg carriers. Gastroenterology (1981) 1.48
Effects of metformin and thiazolidinediones on suppression of hepatic glucose production and stimulation of glucose uptake in type 2 diabetes: a systematic review. Diabetologia (2006) 1.48
Glucose kinetics during high-intensity exercise in endurance-trained and untrained humans. J Appl Physiol (1985) (1995) 1.48
Incidence of hepatitis delta virus infection in acute HBsAg-negative hepatitis. J Infect Dis (1989) 1.48
Epidemiologic patterns of infection with the hepatitis B virus-associated delta agent in Italy. Am J Epidemiol (1983) 1.47
Acute methylprednisolone administration induces a transient alteration of glucose tolerance and pyruvate dehydrogenase in humans. Eur J Clin Invest (1999) 1.47
A new correction factor for use in tracer estimations of plasma fatty acid oxidation. Am J Physiol (1995) 1.47
Enzyme-linked immunosorbent assay for detection of antibody to the hepatitis B surface antigen-associated delta antigen. J Clin Microbiol (1981) 1.47
Roles of glucose transport and glucose phosphorylation in muscle insulin resistance of NIDDM. Diabetes (1996) 1.46
Splanchnic and renal metabolism of insulin in human subjects: a dose-response study. Am J Physiol (1983) 1.43
Interferon and amantadine in combination as initial treatment for chronic hepatitis C patients. J Hepatol (2001) 1.43
Monoethyl glycine xylidide (MEGX) test evaluation in primary biliary cirrhosis: comparison with Mayo score. Eur J Gastroenterol Hepatol (1997) 1.42
Hypouricemia and hyperuricemia in type 2 diabetes: two different phenotypes. Eur J Clin Invest (2001) 1.40
Operation of Randle's cycle in patients with NIDDM. Diabetes (1990) 1.40
Efficacy of azythromicin-based triple therapy for Helicobacter pylori infection: a retrospective study. Panminerva Med (2008) 1.39
Metabolic effects of metformin addition to chronic glibenclamide treatment in type 2 diabetes. Diabete Metab (1994) 1.39
Infliximab for treatment of steroid-refractory ulcerative colitis. Dig Liver Dis (2002) 1.39
Early and longer term effects of gastric bypass surgery on tissue-specific insulin sensitivity and beta cell function in morbidly obese patients with and without type 2 diabetes. Diabetologia (2011) 1.38